Description
Superdrol Oil is the oily injection form of Methasterone. The substance itself is identical with oral Superdrol, just in oily vehicle for intramuscular administration. This bypasses the first pass through the liver.
Per study reports pharmacology remains identical: high-affinity androgen receptor agonist, no aromatization, extreme anabolic potency, dry profile without water retention. Main benefits of the injection are reduced hepatotoxicity and improved bioavailability.
The oral Methasterone form is among the most hepatotoxic anabolics overall - case reports of cholestasis and drug-induced liver injury are frequent. The injection bypasses the intense liver first-pass and measurably reduces ALT/AST burden. But: Methasterone remains 17α-methylated, making the substance hepatotoxic even in injection form - just less drastically than oral.
Pharmacokinetically the oily injection has a longer effective half-life (~8-10 hours) than the tablet (~6-8 hours). Daily injections required.
Known effects are the same as under oral Superdrol: rapid mass gain (3-5kg in 3-4 weeks typical), dry muscle quality, hypertension, unfavorable lipid profile, pronounced HPG suppression. Cycle duration in practice remains limited to 4-6 weeks.
Methasterone is on the WADA banned list.
You can order Superdrol Oil as an oily injection solution in 10-pack at 50mg/ml.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Superdrol Oil bypasses the first-pass effect of the oral form - but the liver burden reduced in the available data does not change the fact that Methasterone is 17-alpha-methylated and oral Methasterone ranks among the most hepatotoxic anabolics overall.
Documented in studies and case reports:
- Hepatotoxicity: oral Methasterone is associated with frequent case reports of cholestasis and drug-induced liver injury. The injection form measurably reduces the ALT/AST burden but remains hepatotoxic due to the 17-alpha-methyl group.
- No aromatization: Methasterone does not aromatize, water retention is not documented. This yields a dry profile but excludes estrogen protective effects.
- Suppression of endogenous production: a pronounced HPG suppression is documented, and recovery after the cycle requires classical PCT in the reports.
- Cardiovascular: the literature describes hypertension and a markedly unfavorable lipid profile. Cycle duration in practice remains limited to 4-6 weeks.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Cholestatic jaundice and IgA nephropathy induced by OTC muscle building agent Superdrol - American Journal of Gastroenterology 2006, Nasr et al: classical case report on methasterone-induced cholestasis.
- Metabolic studies with promagnon, methylclostebol and methasterone in the uPA+/+-SCID chimeric mice - Journal of Steroid Biochemistry and Molecular Biology 2011, Pozo et al: metabolism study of methasterone.
- Anabolic steroid-associated liver injury - Clinical Liver Disease 2024, Stolz et al: current review of AAS-induced hepatotoxicity.
- Androgenic-anabolic steroid drug-induced liver injury - Internal Medicine Journal 2013, Robles-Diaz et al: DILI case series under designer steroids.
- Drug-induced liver injury secondary to anabolic steroid use - Revista de Gastroenterología de México 2020, Petrov et al: DILI data under anabolic use.
